Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred


IMPACT FACTOR 2018: 3.014
5-year IMPACT FACTOR: 3.162

CiteScore 2018: 3.09

SCImago Journal Rank (SJR) 2018: 1.482
Source Normalized Impact per Paper (SNIP) 2018: 0.820

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 392, Issue 1-2

Issues

The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and d-amphetamine

Thomas Steinkellner
  • Centre for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Währingerstrasse 13a, A-1090 Vienna, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Michael Freissmuth
  • Centre for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Währingerstrasse 13a, A-1090 Vienna, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Harald H. Sitte
  • Centre for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Währingerstrasse 13a, A-1090 Vienna, Austria
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Therese Montgomery
  • Centre for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Währingerstrasse 13a, A-1090 Vienna, Austria
  • Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-06-18 | DOI: https://doi.org/10.1515/bc.2011.016

Abstract

Amphetamine (‘Speed’), methamphetamine (‘Ice’) and its congener 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) are illicit drugs abused worldwide for their euphoric and stimulant effects. Despite compelling evidence for chronic MDMA neurotoxicity in animal models, the physiological consequences of such toxicity in humans remain unclear. In addition, distinct differences in the metabolism and pharmacokinetics of MDMA between species and different strains of animals prevent the rationalisation of realistic human dose paradigms in animal studies. Here, we attempt to review amphetamine toxicity and in particular MDMA toxicity in the pathogenesis of exemplary human pathologies, independently of confounding environmental factors such as poly-drug use and drug purity.

Keywords: addiction; amphetamine; disease; 3,4-methylenedioxymethamphetamine (MDMA)

About the article

Corresponding author


Received: 2010-09-14

Accepted: 2010-11-16

Published Online: 2011-06-18

Published in Print: 2011-02-01


Citation Information: Biological Chemistry, Volume 392, Issue 1-2, Pages 103–115, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/bc.2011.016.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Ralph J. Koek and Tinh Luong
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018
[3]
Andreas K. Breitbarth, Jody Morgan, and Alison L. Jones
Drug and Alcohol Dependence, 2018
[4]
Lee E. Dunlap, Anne M. Andrews, and David E. Olson
ACS Chemical Neuroscience, 2018
[7]
Xin Liu, Li-Hui Zhan, Xiao-Hong Sun, Tao Zhang, Zhi-Li Liu, Xiao-Fang Liang, Fei Zhao, Fang Liu, Guang Zeng, and Chun-Sheng Luan
Cutaneous and Ocular Toxicology, 2017, Page 1
[8]
James D. Foster, Jae-Won Yang, Amy E. Moritz, Sathyavathi ChallaSivaKanaka, Margaret A. Smith, Marion Holy, Kyle Wilebski, Harald H. Sitte, and Roxanne A. Vaughan
Journal of Biological Chemistry, 2012, Volume 287, Number 35, Page 29702
[9]
Thomas Steinkellner, Jae-Won Yang, Therese R. Montgomery, Wei-Qiang Chen, Marie-Therese Winkler, Sonja Sucic, Gert Lubec, Michael Freissmuth, Ype Elgersma, Harald H. Sitte, and Oliver Kudlacek
Journal of Biological Chemistry, 2012, Volume 287, Number 35, Page 29627
[10]
Todd Brackins, Nancy C. Brahm, Julie C. Kissack, Stanley S. Weber, and Michael Biglow
Journal of Pharmacy Practice, 2011, Volume 24, Number 6, Page 541
[11]
Isabelle Ayumi Spühler, Andreas Hauri, and Filippo Castiglione
PLoS ONE, 2013, Volume 8, Number 8, Page e71615
[12]
Oliver G. Bosch, Michael Wagner, Frank Jessen, Kai-Uwe Kühn, Alexius Joe, Erich Seifritz, Wolfgang Maier, Hans-Jürgen Biersack, Boris B. Quednow, and Stefano L. Sensi
PLoS ONE, 2013, Volume 8, Number 4, Page e61234
[13]
Natalie R. Sealover, Bruce Felts, Charles P. Kuntz, Rachel E. Jarrard, Gregory H. Hockerman, Eric L. Barker, and L. Keith Henry
Biochemical Pharmacology, 2016, Volume 120, Page 46
[14]
Rubén García-Cabrerizo and M. Julia García-Fuster
NeuroToxicology, 2016, Volume 56, Page 29
[15]
Dan-Ni Cao, Jing-Jing Shi, Wei Hao, Ning Wu, and Jin Li
European Journal of Pharmacology, 2016, Volume 780, Page 129
[16]
Lan Wang, Guoqiang Qu, Xiyuan Dong, Kai Huang, Molly Kumar, Licheng Ji, Ya Wang, Junning Yao, Shulin Yang, Ruxing Wu, and Hanwang Zhang
Toxicology Letters, 2016, Volume 242, Page 1
[17]
Uma Sriram, Bijayesh Haldar, Jonathan M. Cenna, Larisa Gofman, and Raghava Potula
Frontiers in Microbiology, 2015, Volume 6
[19]
Wiener klinische Wochenschrift, 2015, Volume 127, Number 9-10, Page 408
[20]
Ying-Shan Piao, Frank Scott Hall, Yuki Moriya, Miki Ito, Arihisa Ohara, Ruri Kikura-Hanajiri, Yukihiro Goda, Klaus-Peter Lesch, Dennis L. Murphy, George R. Uhl, and Ichiro Sora
Behavioural Pharmacology, 2015, Volume 26, Number 4, Page 345
[22]
Kusumika Saha, John S Partilla, Kurt R Lehner, Amir Seddik, Thomas Stockner, Marion Holy, Walter Sandtner, Gerhard F Ecker, Harald H Sitte, and Michael H Baumann
Neuropsychopharmacology, 2015, Volume 40, Number 6, Page 1321
[23]
Thomas Steinkellner, Liudmilla Mus, Birgit Eisenrauch, Andreea Constantinescu, Damiana Leo, Lisa Konrad, Mattias Rickhag, Gunnar Sørensen, Evgenia V Efimova, Eryan Kong, Matthäus Willeit, Tatyana D Sotnikova, Oliver Kudlacek, Ulrik Gether, Michael Freissmuth, Daniela D Pollak, Raul R Gainetdinov, and Harald H Sitte
Neuropsychopharmacology, 2014
[24]
Elena Puerta and Norberto Aguirre
Pharmaceuticals, 2011, Volume 4, Number 12, Page 992
[25]
Michael H Baumann, Simon Bulling, Tova S Benaderet, Kusumika Saha, Mario A Ayestas, John S Partilla, Syed F Ali, Thomas Stockner, Richard B Rothman, Walter Sandtner, and Harald H Sitte
Neuropsychopharmacology, 2014, Volume 39, Number 6, Page 1355
[26]
L.D. Simmler, A. Rickli, M.C. Hoener, and M.E. Liechti
Neuropharmacology, 2014, Volume 79, Page 152
[27]
Fazlin Mohd Fauzi, Alexios Koutsoukas, Andrew Cunningham, Ana Gallegos, Roumen Sedefov, and Andreas Bender
Human Psychopharmacology: Clinical and Experimental, 2013, Volume 28, Number 4, Page 365
[28]
Emmanuel J. M. Mignot
Neurotherapeutics, 2012, Volume 9, Number 4, Page 739
[29]
Sophie Duong, Kara Chung, and Sharon B Wigal
Expert Opinion on Drug Metabolism & Toxicology, 2012, Volume 8, Number 5, Page 543
[30]
Angelica M. Morales, Buyean Lee, Gerhard Hellemann, Joseph O’Neill, and Edythe D. London
Drug and Alcohol Dependence, 2012, Volume 125, Number 3, Page 230
[31]
Andrew D Westwell, David GE Caldicott, and Alun Hutchings
Future Medicinal Chemistry, 2012, Volume 4, Number 2, Page 129
[32]
L.G. Kirby, F.D. Zeeb, and C.A. Winstanley
Neuropharmacology, 2011, Volume 61, Number 3, Page 421

Comments (0)

Please log in or register to comment.
Log in